entertainment -WSS

entertainment

author：knowledge 2025-09-27 09:57:29 - browse：7

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： FDA cancer chief on how to get things done: ‘Don’t tell anybody'

focus

hotspot

WSS

Ukraine seeks to reclaim its role as a hub for clinical trials

Carbon Health diabetes program, a test of data

New CMS data security rules will hurt Medicare, Medicaid research

What is STAT's opinion section for?

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

Surprise medical billing ban raises prices elsewhere

knowledge

entertainment

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Surprise medical billing ban raises prices elsewhere

Bright Health sells Medicare Advantage business to Molina

Today's health inequities arise from racist U.S. history, say experts

Continuity nursing helped my family in our darkest PICU moments

New study raises questions about niacin and heart health

23andMe had bad news about my health. I wish a person had delivered it

New study raises questions about niacin and heart health

Malaria cases in Florida and Texas: Here’s what you need to know

Surprise medical billing ban raises prices elsewhere

entertainment

Measles policy set amid Florida outbreak alarms vaccine proponents

Type 2 diabetes prevention programs work at large scale: study

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Experimental asthma app from Apple and Anthem shows promise

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

focus

explore

hotspot

focus